mProX™ Human SGK3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX486	Magic™ Human SGK3(SGKL) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;AMO-1;JJN-3;L363;MM.1s

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research;Ocular Research

Related Diseases

Noonan Syndrome 1

Gene ID

Human:23678

UniProt ID

Human:Q96BR1

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SGK3 (serum and glucocorticoid-regulated kinase 3) has various applications in different fields. In cervical cancer, SGK3 promotes cell growth and drug resistance by activating the antioxidant enzyme catalase, and its inhibition enhances the cytotoxicity of certain cancer drugs and overcomes drug resistance. In ischemia-reperfusion injury, SGK3 has a potential role in reducing the damage caused to organs such as the heart and kidney. In superficial esophageal squamous cell neoplasia, SGK3 overexpression is associated with a poor prognosis. In the transition from acute kidney injury to chronic kidney disease, SGK3 regulates renal tubular epithelial cell phenotype and macrophage polarization, potentially impacting the progression of kidney disease. In chemoresistant retinoblastoma, INPP4B (inositol polyphosphate 4-phosphatase type II) overexpression, which is regulated by SGK3, reduces cell viability and tumor growth, suggesting a tumor suppressor role for INPP4B in chemoresistant RB cells.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SGK3 Stable Cell Line (S01YF-1023-PY97). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Davis (Verified Customer)

What role does SGK3 play in cardiac repair after injury? Jan 26 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

SGK3 is activated by CDK9 and promotes cardiac repair after injury through the GSK-3β/β-catenin pathway. Jan 26 2020

chat Alex Williams (Verified Customer)

How does SGK3 affect retinal angiogenesis? Oct 14 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

SGK3 is a target of miR-92a-3p, which regulates retinal angiogenesis, suggesting its potential as an anti-angiogenic factor for retinal vascular diseases. Oct 14 2022

Published Data

Fig.1 Silencing of SGK3 in MM cell lines.

At day 3 post-electroporation, cells were harvested, and phosphorylation levels of Akt and potential SGK3 downstream substrates were measured in stEGFP vs. stSGK3 transfected MM cell lines. Two gels were employed for each cell line, and the representative β-actin control was obtained from the gel also stained for P-Akt (Thr308) (in all cell lines) and pan-Akt (L-363, MM.1s) or P-FOXO1/3A and P-GSK-3β (JJN-3).

Ref: Hausmann, Stefan, et al. "Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines." Plos one 10.4 (2015): e0122689.

Pubmed: 25837824

DOI: 10.1371/journal.pone.0122689

Research Highlights

Wang, Min. et al. "The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance." Redox biology, 2023.
In cervical cancers with PIK3CA helical domain mutations, SGK3 functions as a key factor in promoting cell growth and resistance to drugs by mitigating oxidative stress. When faced with oxidative stress, SGK3 becomes activated and acts as an anti-ROS agent by both enhancing the stability and activation of the antioxidant enzyme catalase. SGK3 accomplishes this by interacting with catalase, phosphorylating it to boost its tetrameric configuration and functionality. Furthermore, SGK3 phosphorylates GSK3β, safeguarding catalase from GSK3β-β-TrCP-mediated ubiquitination and subsequent proteasomal degradation. Inhibiting SGK3 not only enhances the cytotoxic effects of the CDK4/6 inhibitor Palbociclib but also conquers cisplatin resistance through ROS-mediated mechanisms. These findings reveal SGK3's role in preserving redox balance and propose the therapeutic targeting of the SGK3-catalase antioxidant signaling pathway to enhance the treatment outcomes for cervical cancers with PIK3CA helical domain mutations.
Wang, Min. et al. "The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance." Redox biology, 2023.
Pubmed: 37866161 DOI: 10.1016/j.redox.2023.102931

S, Mahmood. "Serum Glucocorticoid-Regulated Kinase-1 in Ischemia-Reperfusion Injury; Blessing or Curse." Journal of Pharmacology and Experimental Therapeutics, 2023.
The serum-glucocorticoid-regulated kinase (SGK) family, consisting of three paralogs (SGK-1, SGK-2, SGK-3), with SGK-1 being the most extensively studied, plays a crucial role in regulating cellular processes, such as survival and proliferation. It has also been implicated in the development of certain cancers, leading to the development of small-molecule inhibitors. Additionally, SGK-1 has been found to regulate important physiological functions, including renal solute transport, and is involved in the pathogenesis of non-neoplastic conditions affecting major organs like the heart and kidney. Therefore, targeting SGK-1 could provide therapeutic benefits in diseases like myocardial infarction and acute kidney injury. This review primarily focuses on the role of SGK-1 in pathologies related to ischemia-reperfusion injury in various organs. With SGK-1's involvement in cell death and its potential to promote cell survival, therapeutic modulation of this protein could have a positive impact on conditions associated with ischemia-reperfusion injury.
S, Mahmood. "Serum Glucocorticoid-Regulated Kinase-1 in Ischemia-Reperfusion Injury; Blessing or Curse." Journal of Pharmacology and Experimental Therapeutics, 2023.
Pubmed: 37770199 DOI: 10.1124/jpet.123.001846